We are live on ! Find out more
MREO icon

Mereo BioPharma

14 hedge funds and large institutions have $4.08M invested in Mereo BioPharma in 2019 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 5 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.49% less ownership

Funds ownership: 1.64% → 1.14% (-0.49%)

13% less funds holding

Funds holding: 16 → 14 (-2)

80% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 5

99% less capital inflows, than outflows

Capital inflows: $14.9K | Capital outflows: $2.27M

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 4

Holders
14
Holders Change
-2
Holders Change %
-12.5%
% of All Funds
0.28%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
–
Increased
1
Reduced
5
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

MREO Hedge Fund Activity: Q4 2019 in Review

14 of the 5,090 institutional investors tracked by Wall St. Rank reported a position in Mereo BioPharma (MREO) for Q4 2019, worth a combined $4.08M — down 22% from $5.21M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of MREO and 0 opened new positions — a net loss of 4 holders — while 5 trimmed existing stakes and 1 added.

The largest buyer was UBS Group, adding an estimated $14.9K. The largest seller was BVF Inc, exiting entirely with an estimated $1.52M sold.

  • 14 institutional investors held Mereo BioPharma (MREO) as of Q4 2019, down from 16 in Q3 2019.
  • Funds reported $4.08M of Mereo BioPharma stock for Q4 2019, down 22% quarter-over-quarter.
  • 0 funds opened new Mereo BioPharma positions in Q4 2019 and 4 closed out, a net change of -4 holders.
  • The largest Mereo BioPharma buyer in Q4 2019 was UBS Group, an estimated $14.9K added.
  • The largest Mereo BioPharma seller in Q4 2019 was BVF Inc, an estimated $1.52M sold.

Based on aggregated 13F filings for Q4 2019.